Nomura Motoo, Oze Isao, Kodaira Takeshi, Abe Tetsuya, Komori Azusa, Narita Yukiya, Masuishi Toshiki, Taniguchi Hiroya, Kadowaki Shigenori, Ura Takashi, Andoh Masashi, Tachibana Hiroyuki, Uemura Norihisa, Tajika Masahiro, Niwa Yasumasa, Muto Manabu, Muro Kei
Department of Clinical Oncology, Aichi Cancer Center Hospital, 1-1 Kanokoden Chikusa-ku, 464-8681, Nagoya, Aichi, Japan.
Department of Therapeutic Oncology, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, 606-8507, Kyoto, Japan.
Int J Clin Oncol. 2016 Oct;21(5):890-898. doi: 10.1007/s10147-016-0963-3. Epub 2016 Mar 15.
Our intent was to compare survival following neoadjuvant chemotherapy followed by surgery versus chemoradiotherapy (CRT) among patients with potentially resectable esophageal squamous cell carcinoma.
Information about 406 consecutive esophageal cancer patients with resectable disease who underwent surgery with neoadjuvant chemotherapy consisting of cisplatin plus 5-fluorouracil or who underwent definitive CRT was reviewed. The survival outcomes were analyzed using the Kaplan-Meier method and propensity score-adjusted Cox proportional hazards models. Relevant variables were included in the propensity score model.
Overall, 206 patients planned to undergo surgery (S group) and 200 patients planned to undergo CRT (CRT group). In the unadjusted situation, progression-free survival and overall survival did not differ statistically between the groups. After matching, both survival outcomes were better in the S group compared to the CRT group. Subanalysis showed both survival outcomes were better in the S group for patients with only stage III disease. However, survival outcomes for stages I, II, and IV were not significantly different between treatment groups.
Among patients with resectable disease, survival outcomes in the S group were favored over those of the CRT group. These results indicate that different therapeutic strategies should be used for stage III esophageal cancer than for other stages.
我们旨在比较新辅助化疗后手术与放化疗(CRT)对潜在可切除食管鳞状细胞癌患者生存率的影响。
回顾了406例连续性可切除食管癌患者的信息,这些患者接受了由顺铂加5-氟尿嘧啶组成的新辅助化疗后进行手术,或接受了根治性CRT。使用Kaplan-Meier方法和倾向评分调整的Cox比例风险模型分析生存结果。相关变量纳入倾向评分模型。
总体而言,206例患者计划接受手术(S组),200例患者计划接受CRT(CRT组)。在未调整的情况下,两组之间的无进展生存期和总生存期在统计学上无差异。匹配后,S组的两种生存结果均优于CRT组。亚分析显示,仅III期疾病患者中S组的两种生存结果均更好。然而,I、II和IV期患者的生存结果在治疗组之间无显著差异。
在可切除疾病患者中,S组的生存结果优于CRT组。这些结果表明,III期食管癌应采用与其他阶段不同的治疗策略。